Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 571 to 580 of 1514 total matches.
A Topical Carbonic Anhydrase Inhibitor For Glaucoma
The Medical Letter on Drugs and Therapeutics • Sep 01, 1995 (Issue 956)
Wilkerson et al, Arch Ophthalmol, 111:1343, 1993).
The Medical Letter, Vol. 37 (Issue 956) September 1 ...
Dorzolamide hydrochloride (Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Intracavernous Injection of Alprostadil for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Sep 29, 1995 (Issue 958)
Letter, Vol. 37 (Issue 958) September 29, 1995, pp. 83-84
Copyright The Medical Letter
UNAUTHORIZED ...
An aqueous formulation of alprostadil (prostaglandin E 1 ; - Upjohn) has been approved by the US Food and Drug Administration (FDA) for injection into the corpus cavernosum to treat erectile dysfunction. The drug is also marketed as Prostin VR, an alcohol-containing formulation, for intravenous use in newborns with congenital heart disease to maintain the patency of the ductus arteriosus.
Itraconazole for Onychomycosis
The Medical Letter on Drugs and Therapeutics • Jan 19, 1996 (Issue 966)
who took
The Medical Letter, Vol. 38 (Issue 966) January 19, 1996, pp. 5-6
Copyright The Medical ...
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.
Umbilical Cord Blood for Bone Marrow Transplantation
The Medical Letter on Drugs and Therapeutics • Aug 16, 1996 (Issue 981)
may be undetectable.
The Medical Letter, Vol. 38 (Issue 981) August 16, 1996, pp. 71-72
Copyright The Medical ...
High-dose chemotherapy followed by bone marrow transplantation continues to be widely used in the treatment of malignant diseases (Medical Letter, 37:25, 1995). The source of the transplant has been autologous or allogeneic bone marrow or, more recently, stem and progenitor cells harvested from peripheral blood (Medical Letter, 37:71, 1995). Now, blood taken from the umbilical cord and placenta of a newborn infant is being tried as a source of cells to restore the bone marrow. A single collection of umbilical cord blood contains about as many progenitor cells as most autologous bone...
Valsartan for Hypertension
The Medical Letter on Drugs and Therapeutics • Apr 25, 1997 (Issue 999)
. Angioedema occurs
The Medical Letter, Vol. 39 (Issue 999) April 25, 1997, pp. 43-44
Copyright The Medical ...
Valsartan (Diovan - Novartis), a non-peptide tetrazole, is the second angiotensin II receptor antagonist approved for oral treatment of hypertension by the US Food and Drug Administration. The first was losartan (Cozaar - Medical Letter, 37:57, 1995).
Ardeparin and Danaparoid for Prevention of Deep Vein Thrombosis
The Medical Letter on Drugs and Therapeutics • Oct 10, 1997 (Issue 1011)
laboratory monitoring.
The Medical Letter, Vol. 39 (Issue 1011) October 10, 1997, pp. 94-95
Copyright ...
Ardeparin sodium (Normiflo - Wyeth-Ayerst), a low-molecular-weight heparin, and danaparoid sodium (Orgaran - Organon), a heparinoid, have been approved by the FDA for prevention of deep vein thrombosis. Without anticoagulation, deep vein thrombosis occurs in up to 30% of patients after abdominal surgery, and in 40% to 70% of patients after major orthopedic operations on the lower limbs. Danaparoid sodium is approved in the USA only for use in hip replacement. Ardeparin is approved here only for use in knee replacement.
Two New Retinoids for Psoriasis
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997 (Issue 1013)
for use in pregnancy.
The Medical Letter, Vol. 39 (Issue 1013) November 7, 1997, pp. 105-106
Copyright ...
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with stable, mild to moderate plaque psoriasis. Acitretin (Soriatane - Roche) is being promoted for systemic use in severe psoriasis.
Zolmitriptan for Migraine
The Medical Letter on Drugs and Therapeutics • Feb 27, 1998 (Issue 1021)
or moderate in intensity and tended to be brief in
The Medical Letter, Vol. 40 (Issue 1021) February 27, 1998 ...
Zolmitriptan (Zomig - Zeneca), a selective serotonin (5-HT1)-receptor agonist, is now available in the USA for oral treatment of migraine headache. Zomitriptan structurally resembles sumatriptan (Imitrex - Medical Letter 34:91, 1992). Drugs currently used for acute treatment of migraine include injectable, oral and nasal spray formulations of sumaptriptan, injectable dihydroergotamine, dihydroergotamine nasal spray, ergotamine tartrate alone or with caffeine, and various analgesics. Anoterh 5-HT1-receptor agonist, naratriptan (Amerge - Gaxo Wellcome), has been approved by the FDA but has not...
Trovafloxacin
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998 (Issue 1022)
. The half-life is
The Medical Letter, Vol. 40 (Issue 1022) March 13, 1998, pp. 30-31
Copyright ...
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
Celecoxib for Arthritis
The Medical Letter on Drugs and Therapeutics • Jan 29, 1999 (Issue 1045)
,
Pharmacotherapy, 18:84, 1998).
The Medical Letter, Vol. 41 (Issue 1045) January 29, 1999, pp. 11-12
Copyright ...
Celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis and rheumatoid arthritis.